The Trump administration has launched a multifaceted campaign to counter what it describes as decades of unfair treatment of American workers, companies, and investors by foreign governments, according to a recent opinion piece by Andrei Iancu and Ambassador Jeffrey Gerrish [1]. While much public attention has focused on tariffs imposed over the past year, President Trump and his advisors emphasize that these measures are intended to reshore supply chains and boost domestic sales and job opportunities for American companies and workers [1].
Beyond tariffs, the administration is also pressuring foreign countries to strengthen protections for American intellectual property (IP), which is seen as crucial for incentivizing innovation and supporting economic growth. IP-intensive industries are highlighted as supporting nearly half of U.S. GDP and more than 62 million jobs [1]. The authors argue that efforts to bolster IP protections may ultimately be more beneficial for American companies, workers, and consumers than tariff policies alone [1].
The pharmaceutical sector is cited as particularly vulnerable to foreign governments' trade practices. American firms, which dominate global drug development, face challenges such as direct price controls, mandatory rebates, regulatory delays, and other tactics that suppress spending on U.S.-made medicines. These practices shift the cost burden for innovation onto American patients [1]. The European Union's recent "General Pharmaceutical Legislation" is noted for reducing market exclusivity periods for new drugs and imposing additional regulatory hurdles, while also considering rules that could force companies to share patented technologies with governments [1].
Mexico is also mentioned for failing to uphold IP commitments made during the USMCA trade deal, allowing generic and biosimilar manufacturers to launch products prematurely without a reliable system to verify existing patents. This undermines American biotech innovators' ability to defend their patent rights [1].
CONCLUSION
The Trump administration's dual approach of tariffs and enhanced IP protection aims to address longstanding trade imbalances and support American innovation. While tariffs have garnered public attention, the push for stronger IP protections could have significant long-term benefits for U.S. industries. Market implications are medium, with potential positive effects for American companies if these policies succeed.